Literature DB >> 32403201

Increased Severity of COVID-19 in People with Obesity: Are We Overlooking Plausible Biological Mechanisms?

Eduardo Tibiriçá1, Andrea De Lorenzo1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32403201      PMCID: PMC7273012          DOI: 10.1002/oby.22887

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   9.298


× No keyword cloud information.
To the Editor: The relationship between obesity and more severe disease in patients with coronavirus disease (COVID‐19) is intriguing. Recent articles published in Obesity (1, 2, 3) discuss the possible effects of increased proinflammatory cytokines and disturbances of lung function in people with obesity, but we believe that they overlook an important player in this scenario, which is endothelial dysfunction. Endothelial dysfunction is present in obesity and is indeed a final common pathway of a cluster of comorbidities, such as hypertension, diabetes, and dyslipidemia. In obesity, the severity of endothelial dysfunction correlates with the degree of visceral adiposity, and studies have indicated the roles of proinflammatory factors and oxidative stress (3). In addition to that chronic scenario, acute endothelial damage occurs, induced by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (which binds to the transmembrane angiotensin‐converting enzyme II receptor). Vascular endothelial cell apoptosis ensues and, in conjunction with the acute “cytokine storm,” promotes the settings for lung microvascular dysfunction, vascular leakage, alveolar edema, and ultimately hypoxia. Proinflammatory cytokines also increase the expression of adhesion molecules, resulting in endothelial activation and procoagulant changes, worsening microvascular flow and tissue perfusion (4). In this context, the acronym “MicroCLOTS” (microvascular COVID‐19 lung vessels obstructive thromboinflammatory syndrome) was recently suggested to describe a progressive endothelial pulmonary syndrome with microvascular thrombosis (5). Therefore, we believe that among several possible pathophysiologic mechanisms leading to adverse prognosis in people with obesity and COVID‐19, endothelial dysfunction is a central one, as it combines the effects of obesity and its associated comorbidities with the acute effect of SARS‐CoV‐2. This should turn our attention to the endothelium; if we overlook that, we may be overlooking important plausible biological mechanisms underlying the association between obesity and more serious COVID‐19 outcomes. Disclosure: The authors declare no conflict of interest.
  5 in total

1.  Cytokine release syndrome in severe COVID-19.

Authors:  John B Moore; Carl H June
Journal:  Science       Date:  2020-04-17       Impact factor: 47.728

2.  Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis.

Authors:  Fabio Ciceri; Luigi Beretta; Anna Mara Scandroglio; Sergio Colombo; Giovanni Landoni; Annalisa Ruggeri; Jacopo Peccatori; Armando D'Angelo; Francesco De Cobelli; Patrizia Rovere-Querini; Moreno Tresoldi; Lorenzo Dagna; Alberto Zangrillo
Journal:  Crit Care Resusc       Date:  2020-04-15       Impact factor: 2.159

3.  Targeting the Adipose Tissue in COVID-19.

Authors:  Alexis Elias Malavazos; Massimiliano Marco Corsi Romanelli; Francesco Bandera; Gianluca Iacobellis
Journal:  Obesity (Silver Spring)       Date:  2020-05-21       Impact factor: 9.298

4.  Does Coronavirus Disease 2019 Disprove the Obesity Paradox in Acute Respiratory Distress Syndrome?

Authors:  Ricardo J Jose; Ari Manuel
Journal:  Obesity (Silver Spring)       Date:  2020-06       Impact factor: 5.002

5.  The Role of Adipocytes and Adipocyte-Like Cells in the Severity of COVID-19 Infections.

Authors:  Ilja L Kruglikov; Philipp E Scherer
Journal:  Obesity (Silver Spring)       Date:  2020-06-10       Impact factor: 9.298

  5 in total
  6 in total

Review 1.  Reviving the mutual impact of SARS-COV-2 and obesity on patients: From morbidity to mortality.

Authors:  Tapan Behl; Sachin Kumar; Sukhbir Singh; Saurabh Bhatia; Ali Albarrati; Mohammed Albratty; Abdulkarim M Meraya; Asim Najmi; Simona Bungau
Journal:  Biomed Pharmacother       Date:  2022-05-24       Impact factor: 7.419

2.  Determinants of endothelial dysfunction in noncritically ill hospitalized COVID-19 patients: A cross-sectional study.

Authors:  Alessandro Domingues Heubel; Ariane Aparecida Viana; Stephanie Nogueira Linares; Vanessa Teixeira do Amaral; Nathany Souza Schafauser; Gustavo Yudi Orikassa de Oliveira; Paula Camila Ramírez; Bruno Martinelli; Tiago da Silva Alexandre; Audrey Borghi-Silva; Emmanuel Gomes Ciolac; Renata Gonçalves Mendes
Journal:  Obesity (Silver Spring)       Date:  2021-11-23       Impact factor: 9.298

3.  Obesity and Disease Severity Among Patients With COVID-19.

Authors:  Imane Motaib; Saad Zbiri; Saloua Elamari; Nezha Dini; Asma Chadli; Chafik El Kettani
Journal:  Cureus       Date:  2021-02-05

4.  Tackling obesity during the COVID-19 pandemic.

Authors:  Amit Akirov; Avivit Cahn; Stefano Del Prato; Philip Home; Luc Van Gaal; Juliana Chan; Guang Ning; Itamar Raz
Journal:  Diabetes Metab Res Rev       Date:  2020-08-29       Impact factor: 8.128

5.  The impact of COVID-19 on obesity services across Europe: A physician survey.

Authors:  Katrin Nather; Fiachra Bolger; Laurie DiModica; Mary Fletcher-Louis; Javier Salvador; François Pattou; Ulrik Haagen Panton; Ana-Paula Cancino
Journal:  Clin Obes       Date:  2021-07-13

Review 6.  A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV.

Authors:  Huan Zhou; Junfa Yang; Chang Zhou; Bangjie Chen; Hui Fang; Shuo Chen; Xianzheng Zhang; Linding Wang; Lingling Zhang
Journal:  Front Med (Lausanne)       Date:  2021-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.